Genzyme Corp Sample Contracts

AMONG
Credit Agreement • March 30th, 2000 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
AutoNDA by SimpleDocs
FIRST SCHEDULE PREMISES
Indenture • November 9th, 2001 • Genzyme Corp • Biological products, (no disgnostic substances)
Acquisition Proposal..........................................................35 Affiliates ....................................................................49 Agreemen t......................................................................1 Assign...
Agreement and Plan of Merger • August 13th, 2003 • Genzyme Corp • Biological products, (no disgnostic substances) • Delaware

ERISA.........................................................................23 ERISA Affiliate...............................................................23 Exchange Act...................................................................2 Expiration Date................................................................2 FDA...........................................................................17 FDCA..........................................................................17 Fee Conversion Options.........................................................9 FTC...........................................................................38 Fully Diluted Shares..........................................................54 GAAP..........................................................................15 Governmental Entity...........................................................14 HSR Act.......................................................................14 Indemnified Liability.......

AMONG
Credit Agreement • March 31st, 1997 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
INDENTURE
Genzyme Corp • May 11th, 2001 • Biological products, (no disgnostic substances) • New York
4,000,000 SHARES GENZYME CORPORATION GENZYME TISSUE REPAIR DIVISION COMMON STOCK UNDERWRITING AGREEMENT
Genzyme Corp • October 30th, 1997 • Biological products, (no disgnostic substances) • New York
COMMON STOCK PURCHASE WARRANT NO. 001
Genzyme Corp • November 9th, 2001 • Biological products, (no disgnostic substances)
EXHIBIT A
Common Stock Purchase Agreement • July 18th, 1997 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
3,000,000 Shares GENZYME CORPORATION Genzyme Molecular Oncology Division Common Stock UNDERWRITING AGREEMENT ----------------------
Underwriting Agreement • June 8th, 1998 • Genzyme Corp • Biological products, (no disgnostic substances) • New York
RECITALS:
Lease • March 15th, 2004 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
PURCHASE AGREEMENT
Purchase Agreement • November 14th, 1997 • Genzyme Corp • Biological products, (no disgnostic substances) • New York
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER
Agreement and Plan of Merger • February 27th, 2004 • Genzyme Corp • Biological products, (no disgnostic substances) • Delaware
LEASE BETWEEN
Genzyme Corp • March 31st, 1999 • Biological products, (no disgnostic substances) • Massachusetts
AutoNDA by SimpleDocs
RECITALS
Supplemental Agreement • January 2nd, 2001 • Genzyme Corp • Biological products, (no disgnostic substances) • New York
ii) 4 AMENDED AND RESTATED RIGHTS AGREEMENT
Rights Agreement • May 1st, 1997 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
GENZYME CORPORATION $500,000,000 3.625% Senior Notes Due 2015 $500,000,000 5.000% Senior Notes Due 2020 REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • June 17th, 2010 • Genzyme Corp • Biological products, (no disgnostic substances) • New York

Genzyme Corporation, a Massachusetts corporation (the “Company”), proposes to issue and sell, upon the terms set forth in a purchase agreement, dated as of June 14, 2010 (the “Purchase Agreement”), U.S. $500,000,000 aggregate principal amount of its 3.625% Senior Notes Due 2015 (the “2015 Notes”) and U.S. $500,000,000 aggregate principal amount of its 5.000% Senior Notes Due 2020 (the “2020 Notes”) (the 2015 Notes and the 2020 Notes are collectively referred to herein as the “Initial Securities”) to the several initial purchasers named in Schedule A to the Purchase Agreement (collectively, the “Initial Purchasers”). The Initial Securities will be issued pursuant to an Indenture, dated as of even date herewith, between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”), as supplemented by the First Supplemental Indenture, dated as of even date herewith, among the Company, the Subsidiary Guarantor(s) party thereto from time to time and the Trustee

EXHIBIT 2 STOCK PURCHASE AGREEMENT BY AND BETWEEN
Stock Purchase Agreement • November 8th, 1999 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
3) GENZYME LIMITED
Genzyme Corp • November 8th, 2005 • Biological products, (no disgnostic substances) • England
ARTICLE I DEFINITIONS
Securities Purchase Agreement • November 9th, 2001 • Genzyme Corp • Biological products, (no disgnostic substances)
GENZYME CORPORATION 3% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2021 REGISTRATION RIGHTS AGREEMENT
Genzyme Corp • May 11th, 2001 • Biological products, (no disgnostic substances) • New York
RECITALS
Stockholder Voting Agreement • April 26th, 2001 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
LEASE
Lease • November 14th, 2000 • Genzyme Corp • Biological products, (no disgnostic substances) • Massachusetts
Time is Money Join Law Insider Premium to draft better contracts faster.